Home / Business and Economy / Sun Pharma Launches Skin Cancer Drug in US
Sun Pharma Launches Skin Cancer Drug in US
16 Jan
Summary
- Sun Pharma has launched its skin cancer drug, Unloxcyt, in the United States.
- The drug treats advanced forms of cutaneous squamous cell carcinoma.
- An estimated 40,000 US patients annually progress to advanced skin cancer disease.
Sun Pharmaceutical Industries has officially launched its novel skin cancer medication, Unloxcyt (cosibelimab-ipdl), in the United States market as of January 16, 2026. This groundbreaking drug is now accessible for healthcare professionals to prescribe to adult patients suffering from metastatic or locally advanced cutaneous squamous cell carcinoma.
The treatment is specifically indicated for patients who have progressed to advanced stages of the disease and are not eligible for curative surgical or radiation therapies. Unloxcyt represents a significant advancement in checkpoint inhibition, aiming to provide both lasting efficacy and a manageable tolerability profile for this vulnerable patient group.
Cutaneous squamous cell carcinoma is a prevalent skin cancer worldwide. In the US alone, nearly 15,000 deaths occur annually, with an estimated 40,000 patients developing advanced disease each year. Sun Pharma's Unloxcyt is distributed through a select network of speciality distributors and pharmacies across the United States.
